Department of Biochemistry, Pt. Jawaharlal Nehru Memorial Medical College, Raipur (CG), 492001, India.
Tumor Biology, ICMR-National Institute of Pathology, New Delhi, 110029, India.
Curr Pharm Biotechnol. 2022;23(6):787-802. doi: 10.2174/1389201022666210719161453.
Human EGFR (epidermal growth factor receptor) family of tyrosine kinase receptors consists of four members, ErbB1-4. Abnormalities in the ErbB family characterize a variety of human cancers, including breast cancer. Tyrosine kinase is recruited by the activated EGFR cell surface receptor, which transmitted signals from the receptor to interact with intracellular signaling pathways and regulate cellular functions and biological processes. Targeting the intracellular signaling pathways has been aided in the drug development that was already in use and more continually being developed. The review article highlights the function of ErbB receptors/ligands, their role in signaling pathways, effective targeted drugs, and a combination of targeted drug strategies in the treatment of breast cancer that could be leading to the novel combination of anticancer drug delivery systems.
人类表皮生长因子受体（EGFR）家族由四个成员组成，分别为 ErbB1-4。ErbB 家族的异常特征存在于多种人类癌症中，包括乳腺癌。酪氨酸激酶被激活的 EGFR 细胞表面受体募集，该受体将信号从受体传递到与细胞内信号通路相互作用，调节细胞功能和生物过程。靶向细胞内信号通路的方法已应用于药物开发，并在不断发展中。综述文章强调了 ErbB 受体/配体的功能，它们在信号通路中的作用，有效的靶向药物，以及在乳腺癌治疗中靶向药物策略的联合应用，这可能导致新型抗癌药物输送系统的联合应用。
